Related references
Note: Only part of the references are listed.Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trial
Mel Krajden et al.
VACCINE (2014)
Immunogenicity of quadrivalent HPV and combined hepatitis A and B vaccine when co-administered or administered one month apart to 9-10 year-old girls according to 0-6 month schedule
Vladimir Gilca et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2014)
Immunogenicity of 2 Doses of HPV Vaccine in Younger Adolescents vs 3 Doses in Young Women A Randomized Clinical Trial
Simon R. M. Dobson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Declining Genital Warts in Young Women in England Associated With HPV 16/18 Vaccination: An Ecological Study
Rebecca Howell-Jones et al.
JOURNAL OF INFECTIOUS DISEASES (2013)
Efficacy of the HPV-16/18 AS04-Adjuvanted Vaccine Against Low-Risk HPV Types (PATRICIA Randomized Trial): An Unexpected Observation
Anne Szarewski et al.
JOURNAL OF INFECTIOUS DISEASES (2013)
A Randomized, Observer-Blinded Immunogenicity Trial of Cervarix® and Gardasil® Human Papillomavirus Vaccines in 12-15 Year Old Girls
Eve Draper et al.
PLOS ONE (2013)
Age of recipient and number of doses differentially impact human B and T cell immune memory responses to HPV vaccination
Kinga K. Smolen et al.
VACCINE (2012)
Immune responses elicited by a fourth dose of the HPV-16/18 AS04-adjuvanted vaccine in previously vaccinated adult women
A. -B. Moscicki et al.
VACCINE (2012)
Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine Follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years
Mark H. Einstein et al.
HUMAN VACCINES (2011)
Proof-of-Principle Evaluation of the Efficacy of Fewer Than Three Doses of a Bivalent HPV16/18 Vaccine
Aimee R. Kreimer et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Potential mechanisms for HPV vaccine-induced long-term protection
Margaret Stanley
GYNECOLOGIC ONCOLOGY (2010)
Antibody and immune memory persistence after vaccination of preadolescents with low doses of recombinant hepatitis B vaccine
Vladimir Gilca et al.
HUMAN VACCINES (2010)
Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women
Nubia Munoz et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Comparison of the immunogenicity and safety of Cervarix™ and Gardasil® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years
Mark H. Einstein et al.
HUMAN VACCINES (2009)
Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years
B. Romanowski et al.
LANCET (2009)
Antibody kinetics among 8-10 years old respondents to hepatitis B vaccination in a low endemic country and the effect of a booster dose given 5 or 10 years later
Vladimir Gilca et al.
VACCINE (2009)
Evolution of type-specific immunoassays to evaluate the functional immune response to Gardasil®
Judith F. Smith et al.
HUMAN VACCINES (2008)
Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine
Sven-Eric Olsson et al.
VACCINE (2007)
Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16
XJS Chen et al.
MOLECULAR CELL (2000)
Share Paper
